Fluoxetine treatment and single psychotropic comedication: is there an increase in adverse event rates?


After the market launch of fluoxetine (Flx) in Germany in 1990 several series of drug utilization observation studies were carried out under naturalistic conditions (approximately 19,000 patients). This paper focuses on 3158 patients from neuropsychiatric practices comparing adverse event rates plus additional variables in patient groups treated with Flx… (More)